ReviewArchivos de bronconeumologia2021
[Thrombotic Risk and Covid-19: Review of Current Evidence for a Better Diagnostic and Therapeutic Approach].
Review in Archivos de bronconeumologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Epidemiology of the COVID-19 pneumonia in a group of hospitals from Madrid-Spain during the full period of the State of Alarm HM cohort.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Observational
- A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study.Cardiovascular diagnosis and therapy · 2023Review
- [Assessment of pulmonary embolism related to active SARS-CoV-2 infection in pregnant women.]Revista espanola de medicina nuclear e imagen molecular · 2022Article
- [Ischaemic stroke due to basilar artery occlusion in a puerperal patient with SARS-CoV-2 infection].Revista de neurologia · 2022Article
- Impact of the SARS-CoV-2 Virus Pandemic on Patients with Bronchiectasis: A Multicenter Study.Antibiotics (Basel, Switzerland) · 2022Article
- Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.Archivos de bronconeumologia · 2022Review
- Plasma D-dimer value corrected by inflammatory markers in patients with SARS-CoV-2 infection: Its prognostic value in the diagnosis of venous thromboembolism.Medicina clinica (English ed.) · 2022Article
- Plasma D-dimer value corrected by inflammatory markers in patients with SARS-CoV-2 infection: Its prognostic value in the diagnosis of venous thromboembolism.Medicina clinica · 2022Article
- Mechanical Valve Thrombosis Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report.Cureus · 2022Article
- [Enoxaparin dose associated with decreased risk of death in COVID-19].Revista medica del Instituto Mexicano del Seguro Social · 2022Observational
- Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach.Journal of thoracic disease · 2021Review
- Assessment of pulmonary embolism related to active SARS-CoV-2 infection in pregnant women.Revista espanola de medicina nuclear e imagen molecularArticle
- [SEPAR Recommendations for COVID-19 Vaccination in Patients With Respiratory Diseases].Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new SARS-CoV-2 coronavirus has created an unprecedented global health problem, resulting in more than 250,000 confirmed deaths. The disease produced by this virus, called Covid-19, presents with variable clinical manifestations, from practically asymptomatic patients with catarrhal processes to severe pneumonias that rapidly evolve to acute respiratory distress syndrome (ARDS) and multiorgan failure. In recent weeks, papers have been published describing coagulation disorders and arterial and venous thrombotic complications in these patients, mainly among those admitted to intensive care units. The infection triggers an immune response, which causes different inflammatory mediators to be released into the blood. These include cytokines, which interact with platelets and different coagulation proteins, and promote thrombogenesis. One of the most widely studied coagulation markers in Covid-19 is D-dimer (DD), raised levels of which have prognostic implications, although the best cut-off point for the diagnosis of venous thromboembolism (VTE) in this population has not been clarified, nor has its usefulness in determining the intensity of thromboprophylaxis required in these patients. Until sufficiently robust information (preferably from well-designed clinical trials) is available, the recommendations of clinical practice guidelines for the prophylaxis, diagnosis and treatment of VTE should be followed in Covid-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.